Showing 3841-3850 of 5623 results for "".
- Cognition Therapeutics Doses First Patient in MAGNIFY Study of Oral CT1812 for GA Secondary to Dry AMDhttps://modernod.com/news/cognition-therapeutics-announces-dosing-of-first-patient-in-magnify-study-of-oral-ct1812-for-ga-secondary-to-dry-amd/2481714/Cognition Therapeutics announced that it has dosed the first participant in the phase 2 MAGNIFY study of CT1812, an experimental therapy being developed for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The MAGNIFY study (COG2201,
- Nicox Estimates Potential Annual Global Net Sales for NCX 470 of Over $300 Millionhttps://modernod.com/news/nicox-estimates-potential-annual-global-net-sales-for-ncx-470-of-over-300-million/2481712/Nicox SA said it that annual global net sales of NCX 470 could be over $300 million within 8 years of the date of launches in the U.S. and China. The estimate was based on a US market survey evaluating the commercial potential of NCX 470, a nitric oxide (NO)-donating bima
- Elios Vision Announces Collaboration with the International Glaucoma Surgical Registryhttps://modernod.com/news/elios-vision-announces-collaboration-with-the-international-glaucoma-surgical-registry/2481708/Elios Vision has announced its collaboration and support for the International Glaucoma Surgical Registry (IGSR), an open access tool which enables surgeons to upload and analyze their data and compare outcomes with other centers. The IGSR was established more than 5 years ago and currently
- Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Trial of ADX‑2191 in Patients with RPhttps://modernod.com/news/aldeyra-therapeutics-announces-improvement-from-baseline-in-retinal-function-in-phase-2-clinical-trial-of-adx2191-in-patients-with-rp/2481703/Aldeyra Therapeutics announced positive topline results from the phase 2 clinical trial of intravitreal ADX-2191 (methotrexate injection, USP), an investigational drug candidate, in patients with retinitis pigmentosa (RP). Relative to baseline, the clinical trial demonstrated statistically s
- Visgenx Announces Positive Results from a Key Translational Study for its Gene Therapy Candidate for Dry AMDhttps://modernod.com/news/visgenx-announces-positive-results-from-a-key-translational-study-for-its-gene-therapy-candidate-for-dry-amd/2481700/Visgenx announced positive data from a non-human primate study. The translational study used a single subretinal injection to deliver VGX-0111 (carrying an ELOVL2 transgene) to investigate whether VGX-0111 expresses in the target tissues and causes an increase in certain very long chain
- SriniVas R. Sadda, MD, Named 2023-2024 ARVO President Electhttps://modernod.com/news/srinivas-r-sadda-md-named-2023-2024-arvo-president-elect/2481697/Doheny Eye Institute announced that SriniVas R. Sadda, MD, was named President Elect of the Association for Research in Vision and Ophthalmology (ARVO) during its 2023 annual meeting in New Orleans. Dr. Sadda has been a member of ARVO for a number of years, and s
- FDA Does Not Approve Regeneron's High-Dose Aflibercepthttps://modernod.com/news/fda-does-not-approve-regenerons-high-dose-aflibercept/2481695/Citing "an ongoing review of inspection findings at a third-party filler," the FDA declined to approve Regeneron's aflibercept 8 mg for the treatment of patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR).</
- Myra Vision Announces Funding to Advance Calibreye Surgical Treatment for Glaucoma Patientshttps://modernod.com/news/myra-vision-raises-money-to-advance-calibreye-surgical-treatment-for-glaucoma-patients/2481694/Myra Vision, which is a Shifamed portfolio company, announced the closing of its $25 million Series B financing to further product development, scale manufacturing capabilities, and support first-in-human investigation of the company's Calibreye System, a novel treatm
- Luminopia Raises Money to Support Full Commercial Rollout of Amblyopia Therapeutichttps://modernod.com/news/luminopia-raises-money-to-support-full-commercial-rollout-of-amblyopia-therapeutic/2481692/Luminopia announced it has raised an additional $16 million in new capital to support the full commercial rollout later this year of the company’s lead product, Luminopia, a software-based therapeutic for amblyopia, the leading cause of vision loss among children. Luminopia w
- Euclid Announces ABB Optical Group as Licensed Manufacturer and Distributor of Euclid Ortho-K Lenseshttps://modernod.com/news/euclid-announces-abb-optical-group-as-licensed-manufacturer-and-distributor-of-euclid-ortho-k-lenses/2481691/Euclid Vision has announced that ABB Optical Group is now a licensed manufacturer and distributor of the company’s Ortho-K lenses. Financial terms of the deal were not disclosed. ABB, which Euclid says is the largest distributor of soft lenses in the United States,